Cargando…
Somatic FGFR3 Mutations Distinguish a Subgroup of Muscle-Invasive Bladder Cancers with Response to Neoadjuvant Chemotherapy
The administration of neoadjuvant chemotherapy (NAC) preceding radical cystectomy benefits overall survival for patients with muscle-invasive bladder cancer (MIBC). However, the relationship between the genetic profiling of MIBC and NAC response remains unclear. Here, a mutation panel of six cancer-...
Autores principales: | Yang, Zhao, Zhang, Ruiyun, Ge, Yunxia, Qin, Xuying, Kang, Xing, Wang, Yue, Zhang, Xu, Song, Chengli, Quan, Xiaofang, Wang, Haifeng, Chen, Haige, Li, Chong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6154770/ https://www.ncbi.nlm.nih.gov/pubmed/29941343 http://dx.doi.org/10.1016/j.ebiom.2018.06.011 |
Ejemplares similares
-
BCMab1-Ra, a novel immunotoxin that BCMab1 antibody coupled to Ricin A chain, can eliminate bladder tumor
por: Li, Chong, et al.
Publicado: (2016) -
Aberrantly glycosylated integrin α3β1 is a unique urinary biomarker for the diagnosis of bladder cancer
por: Jin, Di, et al.
Publicado: (2020) -
Mutations of METTL3 predict response to neoadjuvant chemotherapy in muscle-invasive bladder cancer
por: Yang, Zhao, et al.
Publicado: (2021) -
Immunotherapy in the Treatment of Urothelial Bladder Cancer: Insights From Single-Cell Analysis
por: Zang, Jingyu, et al.
Publicado: (2021) -
Neoadjuvant immunotherapy, chemotherapy, and combination therapy in muscle-invasive bladder cancer: A multi-center real-world retrospective study
por: Hu, Jiao, et al.
Publicado: (2022)